AACR 2023: BCG008, A Human Siglec-15 Blocking Antibody, Displays Potent Anti-Tumor Activity in Siglec-15-Humanized Mice
Conclusions
BCG008 has higher hSIGLEC-15 & fasSIGLEC-15 affinity and recognizes a different epitope than 5G12
BCG008 reverses SIGLEC-15 mediated T cell suppression in a dose-dependent manner
BCG008 has a longer half-life than 5G12 (9.79 days vs. 4.19 days)
BCG008 has strong antitumor efficacy and a good safety profile in vivo
BCG008 is a novel, fully human anti-SIGLEC-15 antibody generated from RenMabTM mice
BCG008 has higher hSIGLEC-15 & fasSIGLEC-15 affinity and recognizes a different epitope than 5G12
BCG008 reverses SIGLEC-15 mediated T cell suppression in a dose-dependent manner
BCG008 has a longer half-life than 5G12 (9.79 days vs. 4.19 days)
BCG008 has strong antitumor efficacy and a good safety profile in vivo
+86-010-56967680
010-56967601
ir@bbctg.com.cn
Copyright © 2024 Biocytogen. All Rights Reserved
Powered by Fractal-technology